Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Zhittya Genesis Medicine wins lawsuit. As reported on this message board- what does that mean for Venturis?
Daniel C Montano speaks in Dubai at Family Offices Summit. Should Venturis be at meetings like these?
Zhittya Genesis Medicine set to treat Parkinson's disease patients in Mexico. They have been given approval to start! Where is Venturis on this?
Daniel C Montano announces that Zhittya Genesis Medicine will develop its own proprietary cardiac catheter to advance their heart trials. What catheter will Venturis be using?
Zhittya Genesis Medicine reports on potential new application to use FGF to treat lupus? Is this something Venturis science guys should look at?
When will CVBT ever do Clinical Trials?
Despite our new administration having the opportunity to restart clinical trials for the last six years, we have yet to make any progress whatsoever. Dan Montano's Zhittya Genesis Medicine has started new clinical trials in Parkinson's Disease and ALS with their new manufactured FGF-1. Cardiovascular BioTherapeutics/Venturis Therapeutics has not made new FGF-1 in over half-of-a-decade and has seen no progress whatsoever since Dan Montano left the company in 2014.
When will we start doing clinical trials? What have we been doing in the past six years to prepare for the restarting of our clinical trials? Do we even have new FGF-1 for those clinical trials???
CVBT/Venturis Therapeutics Misconduct results in Dan Montano's $1 million dollar judgement against CVBT/VT
Daniel Montano, founder of CVBT in 1998, left the company in 2014 to found Zhittya Genesis Medicine. CVBT/VT has since filed countless lawsuits, only to lose EVERY SINGLE LAWSUIT to Daniel C. Montano and Zhittya Genesis Medicine. The most recent lawsuit CVBT/Venturis Therapeutics filed against Zhittya Genesis Medicine and Daniel C. Montano has resulted in Zhittya Genesis Medicine being dismissed from the lawsuit, and Daniel Montano having a $1 million dollar judgement against CVBT/VT for their misconduct.
What will this million dollar judgement mean for the future of CVBT/VT? With an upcoming debtors exam for CVBT/VT how can we still raise money?
Zhittya Genesis Medicine dismissed from CVBT's Lawsuit
Cardiovascular Biohtherapeutics' lawsuit claiming that Zhittya Genesis Medicine stole Intellectual Property (IP) from CVBT/Venturis Therapeutics has been dismissed by the Nevada State Court, forcing CVBT/VT to acknowledge that Zhittya Genesis Medicine owns all of the IP it is now developing.
What does the ruling mean for CVBT?
Daniel C Montano with his newly won judgement will probably be heading to Texas to seize some of those tasty Venturis' assets! Yum, Yum.
Zhittya Genesis Medicine reports they are looking at intranasal delivery of FGF - We Venturis should check that out.
Daniel C Montano states that the pre-IPO for the Latin America marketing company will be closing soon - why is Venturis not raising money this way? Why is no one answering these questions?
Daniel C Montano and Zhittya Genesis Medicine are, in my opinion, real and serious competition for us at Venturis. Whoever gets FGF to market first will have a monopoly I am told. We better get moving!!
Zhittya Genesis Medicine has great webinars on their webpage. Where are Venturis' webinars?
Zhittya Genesis Medicine reports FGF-1 may be a potential treatment for autism. Has Venturis looked into this? This is an awful disease for kids.
No, a reduction in Montano's liability to Venturis. Montano was able to show he did not owe 2.7 M only 1.7 M. Thats all
CVBT Progress Update 2021?
Unfortunately, until recently this board has not been active on informing the shareholders of any news that CVBT/Venturis Therapeutics has in 2021. Since our administration feels that they cannot publicly share updates and news I have compiled a list of some things that I have found about CVBT/Venturis Therapeutics from 2021. If you have anymore please feel free to add:
*Lost another major court battle to Dan Montano resulting in Dan Montano's $1 million dollar judgement against CVBT, confirmed by the United States Federal Court
*Zhittya Genesis Medicine, among other defendants, were dismissed from CVBT's/Venturis Therapeutics' lawsuit.
*Yet another shareholders meeting has been scheduled, but as with the last ones will be postponed for another year.
*Our administration has yet to take any action to start drug production or revitalize the clinical trials.
*CVBT/Venturis Therapeutics has fallen even further behind Zhittya Genesis Medicine, as Zhittya Genesis Medicine now has FGF-1 completed and ready to go for their new and active clinical trials in Parkinson's Disease and ALS.
Other than those listed, has there been any other important news or updates regarding CVBT?
Where will CVBT get their catheters???
Zhittya Genesis Medicine has announced that they are now developing their own catheters for their future clinical trials. Such an innovation would likely give Zhittya Genesis Medicine a cutting edge over CVBT/Venturis Therapeutics, which has yet to even produce the FGF-1 molecule, already putting CVBT behind Zhittya Genesis Medicine by about 1-2 years.
If CVBT/Venturis Therapeutics makes the molecule and restarts the clinical trials after nearly a decade of inactivity, will we have to buy our catheters from Zhittya Genesis Medicine? If we have to buy our catheters from them how will that affect CVBT's strategy in the future?
UPCOMING DEBTORS EXAM
With Dan Montano's $1 million dollar judgement, confirmed by the United States Federal Court, against CVBT/Venturis Therapeutics a debtors exam is likely to happen. Since this claim appears unable to be offset by Venturis Therapeutics/CardioVascular BioTherapeutics (CVBT) how would a debtors exam affect the future of the company?
Would the debtors exam result bring forth the true financials of CVBT/Venturis Therapeutics? If it were to bring forth the true financials of our company, would that result in the deterioration if not shutting down of CVBT/Venturis Therapeutics?
Will our shareholders meeting address this pressing issue or will it be postponed again?
Dan Montano's Clear Victory over CVBT
CardioVascular BioTherapeutics/Venturis Therapeutics has lost yet another court battle to Dan Montano. As a result of this miserable defeat, the US Federal Court has confirmed Dan Montano's $1 million dollar judgment against CVBT/Venturis Therapeutics despite bringing on the case themselves!
Despite what individuals say on this page, there is no right of offset to this matter! Dan Montano's $1 million dollar judgement has no offset. The Court Records clearly indicate the Dan Montano's $1 million dollar judgement. Those same Court Records DO NOT INDICATE THAT VENTURIS THERAPEUTICS IS OWED ANYTHING FROM DAN MONTANO. There is no right of offset. We can only hope that Dan Montano will not initiate a debtor's exam.
Grant Gordon and Others have been WRONG for SEVEN YEARS
Many individuals from the CVBT/Venturis Therapeutics administration, including Grant Gordon amongst others, have consistently prophesied the impending downfall of Zhittya Genesis Medicine. If this were the case then:
Why has CVBT/Venturis Therapeutics lost every court battle to Dan Montano and Zhittya Genesis Medicine?
Why does Dan Montano have a judgement against CVBT/Venturis for $1 million dollars?
Why did Myerson, and other CVBT/VT experts, openly admit that our administration was lying when they brought fourth a suit to Zhittya Genesis Medicine and Dan Montano?
Why has the last seven years of professing of downfall only seen Zhittya Genesis Medicine and Dan Montano get stronger?
Why has Zhittya Genesis Medicine moved to creating FGF-1 and starting clinical trials while CVBT has yet to create FGF-1 and has not seen clinical trial activity in almost a decade?
DAN MONTANO STARTED THE CLINICAL TRIALS FOR CVBT
The members of this board are quick to argue that the former leadership has failed completely. On the contrary, the same clinical trails that our leadership touts as successes were started by Dan Montano, and have yet to move since Dan Montano left the company in 2014. The CVBT/Venturis Therapeutics leadership has been advertising their success from the past successes of Dan Montano, who now is successfully running Zhittya Genesis Medicine which has now created new FGF-1 and is starting clinical trials.
I cannot point to a single thing our leadership has done in the past 7 years that are on par with Phase II clinical trials which Venturis Therapeutics inherited from Dan Montano's efforts. What have we done in the last seven years other than IP?
VT Shareholder meeting in late June 2021.
JBDC, I heard the same thing that the meeting is tabled for June. I am really looking forward to it. As I understand it there is going to be some "very interesting" news coming out in the next few weeks.
Can't wait!
Great post, JBDC. As JBDC mentions, anyone who wishes to obtain relevant, up to date information on VT should contact Grant Gordon (the founder of VT). Like me, if you sign a confidentiality agreement he will send you a copy of the presentation which is informative. It is very professional.
Zhittya have to do webinars & the Money Shows to try to shake loose cash from the senior citizens who attend these events. Zhittya has zero institutional investors as Dan Montano cannot pass muster with serious investors. His history of destroying every business he's been involved in is an anathema for serious investors. No institution would invest into a company with a deadbeat CEO such as Dan.
Zhittya Genesis Medicine giving webinars in Dubai. Any upcoming webinars for Venturis on their efforts?
Zhittya Genesis Medicine is CardioVascular Biotherapeutics (Venturis Therapeutics) only competitor in the development of FGF-1. Zhittya Genesis Medicine was founded by the former CEO and founder of CVBT, Dan Montano. Zhittya Genesis Medicine has since soared to the top since he left CVBT in 2014.
Under the Marketplace Exclusivity, the first company to obtain approval gets an effective monopoly for 10 years. With Zhittya Genesis Medicine (ZGM) indubitably ahead of Venturis Therapeutics by about six years, it is clear who will be the first to monopolize the FGF-1 industry.
Zhittya Genesis Medicine and Venturis/CVBT are the only two companies in the race to commercialize FGF-1. Clearly Zhittya Genesis Medicine is far ahead of Venturis in the race as their announcements clearly state that they now have a large batch of FGF-1 at their disposal, have started numerous clinical trials such as in Parkinson's Disease and ALS, have had countless webinars whose social media campaign has touched tens of millions of people, with their subscriber list at tens of thousands.
CVBT/Venturis has now lost Myerson, CVBT has now lost yet another major court battle, Venturis has now lost the majority of their administration. What do we have? There are no experts running Venturis Therapeutics, those experts fled the company after they testified in court that CVBT was lying!
With Daniel C. Montano's $1 million dollar judgement against CVBT/Venturis Therapeutics (WHICH CVBT/VENTURIS HAS NO OFFSET) it is clear that Dan Montano will be coming after Cardiovascular Biotherapeutics.
Every Cardiovascular Biotherapeutics/Venturis Therapeutics shareholder has to keep up with Zhittya Genesis Medicine because they are our only competition! Our competition is leaving us in the dust, without a doubt they are six years ahead of us!
Ultimately I must ask, Zhittya Genesis Medicine has proven that in 6 years a lot of progress can be made. Where is CVBT/Venturis Therapeutics progress? We have made no drug, we have had no shareholders meeting, we have done nothing but lose court battle after court battle in the last half decade. We are losing. When will our CVBT management respond?
Every CVBT shareholder should care.
Why so many posts on Zhittya Genesis Medicine and not Venturis?
Zhittya Genesis Medicine announced that it has been approved to start a clinincal trial in ALS patients in Mexico. Is Venturis pursuing this medical indication? Why is no one from CVBT answering this?
DAN MONTANO OWES VT $1.7 MILLION
How can a bankrupt such as Dan possibly pay off this amount of award. VT must be happy as will the majority of VT shareholders.
Interesting. Please post the case details. I searched on PACER and there is no mention of any case brought by CVBT. Also, I'm interested in how you could you possibly know of any details on what CVBT people said??
Very strange!!
Zhittya Genesis Medicine announced they will starting a Parkinson's disease clinical trial in a few months. What is the status of Venturis (CVBT) study?
Seems to me Montano now only owes Venturis 1.7 million in which they will never receive. The tit for tat 1 million will wash and Venturis will keep plodding on. Nothing more needs to be said.
Zhittya Genesis Medicine DISMISSED from CVBT Lawsuit
In a lawsuit Cardiovascular Biotherapeutics filed against Zhittya Genesis Medicine, the Nevada State Court has dismissed Zhittya Genesis Medicine from the lawsuit. The lawsuit had that claimed that Zhittya Genesis Medicine was stealing trade secrets from CVBT which has since been thrown out of court.
The case was easily dismissed after CVBT'S OWN EXPERTS TESTIFIED THAT ZHITTYA GENESIS MEDICINE STOLE NOTHING FROM CVBT.
In a clear victory for Zhittya Genesis Medicine and Dan Montano, whose $1 million dollar judgement against Venturis Therapeutics will likely result in the downfall of CVBT, investors, including myself are wondering if CVBT will make it through 2021.
By the way, Zhittya Genesis Medicine in their Update also reports the development of intranasal delivery of their products. Is this something we should Venturis should be looking into?
Zhittya Genesis Medicine's Update reports they are developing a new cardiac catheter. Are we???
FEDERAL COURT CONFIRMS DAN MONTANO’S $1 MILLION DOLLAR CLAIM AGAINST CVBT
Mr. Dan Montano’s court victory confirmed by the federal court gives Mr. Montano an incredible vantage. With the universality of the federal court system this makes the claim good throughout the entire nation. In all 50 states and all territories of the United States CVBT owes Dan Montano $1 million dollars and attorney fees. This means that this decision is not only good in state of Nevada (where our former headquarters were), but also in the state of Texas!
I am genuinely concerned for the future of CVBT! With Dan Montano’s incredible vantage it is likely that CVBT won’t even make it through the debtors exam!
It was an award from a certain retired judge, Zimmerman. Nothing to do with Federal Courts.
My question is where the heck will Dan Montano get $1,700,000 to repay VT (the $2,500,000 award to Wallen, now VT, less the $800,000 awarded in back wages to DM)?
Also, as DM is still in bankruptcy will his creditors take action to get hold of the $800,000?
I've heard that the Shareholder Meeting has been slated for June 2021. As I understand it it'll be announced shortly together with some other very interesting and positive news. From my keyboard to GOD'S ears.
I believe this is a big deal for VT, particularly as it has the IP protection around it. In the most recent presentation from VT it has a statement from Chairman of the Board of Directors, Novo Nordisk as follows:-
Patents at the Core: the Biotech Business
World Intellectual Property Organisation - WIPO
“Anyone, I would imagine, who has tried
to create a biotech company knows just how important patents are. You learn this when you’re studying, and again at your first job, and if you haven’t done so before, you realize it the first time you
meet potential investors.”
Mads Øvlisen, Chairman of the Board of
Directors, Novo Nordisk
I would like to share the presentation with y'all but as I signed an NDA before they would send it to me, I need to check out whether I'd get into trouble for sending a link to it here.
I hope everyone has a great weekend.
Johnny & all other "VT supporters" you appear to have missed my post yesterday. I am happy to reiterate.
"I have excellent news for you Johnny & all other VT supporters. The judgement (which had nothing to do with Federal Court, it was arbitration), amounts to slightly over $800,000 of back wages. The problem for Dan is that the $2.5 million awarded to Calvin Wallen a few years ago has been assigned to VT so Dan now owes VT $1.7 million. I am sure that's a relief to all concerned. Where do you think that Dan Montano, who is still bankrupt, will be able to come up with that sort of cash?
I guess good old Dan is in a bit of a pickle.
A sad day all round for Zhittya & Dan Montano personally.
By the way, this information came from someone very closely involved in these matters."
DEBTORS EXAM FOR CARDIOVASCULAR BIOTHERAPEUTICS (CVBT)/VENTURIS THERAPEUTICS
Rumor has it that as a result of Dan Montano's court victory, which has given him a judgment of a $1 million dollar claim against Venturis Therapeutics, confirmed by the Federal Court, that Dan Montano will be seeking a debtors exam for CVBT in the month of May. I am worried that this debtors exam will reveal the true financial position of CVBT/Venturis Therapeutics and make the CVBT directors liable.
How will this debtor's exam affect the future of CVBT? Will there be a future for CVBT following this major legal victory for Daniel C. Montano? Where will CVBT get the $1 million dollars to pay Mr. Dan Montano?
THE UNITED STATES FEDERAL COURT HAS CONFIRMED DAN MONTANO'S ONE MILLION DOLLAR CLAIM AGAINST CVBT/VENTURIS THERAPEUTICS
Furthermore, with Zhittya Genesis Medicine and Mrs. Montano being ENTIRELY DISMISSED from the lawsuits that Venturis brought fourth there is a clear path for Mr. Daniel Montano to forcibly collect on his 1 million dollar claim. Venturis is at the hands of Dan Montano! Why were we not made aware of this? Why is our administration so quick to announce when lawsuits are filed but not when we are miserably defeated and punished for our defeat?
I worry that Mr. Montano will wipe Venturis off the face of the map with his new ability to forcibly collect on his one million dollar award which has been confirmed by the United States Federal Court.
I presume that the news that people may need a COVID booster shot each year, similar to the flu shot, that Venturis' COVID program will be much more valuable now, particularly with the new IP surrounding it.
It wasn't a lawsuit it was arbitration. As far as I'm aware the language in the arbitrator's report was that VT could pay the award when it suited its cash-flow. Regarding the amount Dan Montano owes Venturis, maybe we should have a whip round to see if we can help Dan with amount he owes. I will put up $10 - anyone else?
I am new to this. It sounds like good news but why does Dan Montano owe VT $1.7m? Is that why Dan Montano is bankrupt?
I forgot the other bit of good news. The case between Gloria's Ranch & Tauren (Calvin Wallen) has been settled by the parties out of court. In fact I was just on the PACER website & it confirms the case is closed as per:
Filed & Entered: 04/12/2021
Docket Text Close adversary case
That must be a relief to all posters on the board.
I have excellent news for you Johnny & all other VT supporters. The judgement (which had nothing to do with Federal Court, it was arbitration), amounts to slightly over $800,000 of back wages. The problem for Dan is that the $2.5 million awarded to Calvin Wallen a few years ago has been assigned to VT so Dan now owes VT $1.7 million. I am sure that's a relief to all concerned. Where do you think that Dan Montano, who is still bankrupt, will be able to come up with that sort of cash?
I guess good old Dan is in a bit of a pickle.
A sad day all round for Zhittya & Dan Montano personally.
By the way, this information came from someone very closely involved in these matters.
I guess Zhittya Genesis Medicine and Daniel Montano will now be taking off and devaluing the position of us CVBT Shareholders. Venturis (CVBT) made it sound like they won the lawsuit!
Zhittya Genesis Medicine Inc., (formerly known as Zhittya Regenerative Medicine), competitor to Cardiovascular Biotherapeutics Inc., has announced its CEO, Daniel C. Montano, has been awarded an over $1 million legal judgement, confirmed by the US Federal Court, against CVBT and its new name, Venturis Therapeutics.
Mr. Dan Montano is now pursuing the involuntary collections of his judgements against CVBT.
Zhittya Genesis Medicine also announced that ALL legal allegations made against Zhittya Genesis Medicine have been DISMISSED by the judge.
After seven years of lawsuits by CVBT against Zhittya it is clear that CVBT has come out as the ultimate loser after this judgement against them for $1 million. In all this time, CVBT has FAILED TO CONDUCT CLINICAL TRIALS, MANUFACTURE THE DRUG, OR PAID ANY PART OF ITS $30 MILLION IN DELINQUENT BILLS.
This is the final nail in the coffin.
Sayanora and goodbye, Venturis/CVBT.
But maybe we'll hear all the great news taking place at the 2021 shareholders meeting in May 2021, right?
Followers
|
39
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3648
|
Created
|
04/08/05
|
Type
|
Free
|
Moderators |
VENTURIS THERAPEUTICS (formerly Cardiovascular
Biotherapeutics or CVBT) is a dead, zombie company
that hasn't run a single clinical trial in nearly 15
years. Not even one patient (!) has been treated
since 2007. Venturis Therapeutics is insolvent,
illiquid, and is controlled and run by an individual
who was accused by the U.S government of
embezzling $14 million from his previous company.
Venturis' lawyer, Barry Cannaday of Dentons (one
of the largest law firms in the U.S.), withdrew from
representing Venturis in April 2021 because Dentons
is owed over $200,000 by Venturis, and Mr. Cannaday
attested that "there are currently no assets or
revenue streams" to pay Dentons. Yet anonymous
advocates for Venturis (who I personally believe are
the company's desperate leadership) lie about public
facts that are easily verifiable. One of the most
absurd false claims is that there are (allegedly) two
ongoing pivotal clinical trials (see that particular
false claim below). These "clinical trials" exist only
in cyberspace but not in the real world the rest of us
(including Dentons) live in. That said, enjoy the
entertainment that lies below. Hopefully it gives you
some good laughs - that's about all that's left from
this dead, zombie company. Enjoy!
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS OVERVIEW
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage biopharmaceutical company advancing novel
therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and
peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction,
infarct stroke, degenerative disk disease and Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on targeted delivery of next generation
molecules which will improve the quality of life for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when administered to ischemic organs and
tissues. These anatomical targets are shown in our pipeline section.
vt.care
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |